<SEC-DOCUMENT>0001628280-24-020010.txt : 20240502
<SEC-HEADER>0001628280-24-020010.hdr.sgml : 20240502
<ACCEPTANCE-DATETIME>20240502161006
ACCESSION NUMBER:		0001628280-24-020010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240502
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240502
DATE AS OF CHANGE:		20240502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		24908298

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20240502.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7576a009-f97d-4232-a9b6-7afd7f5ded2e,g:b49e9c80-d4d3-4f5c-b13c-b31d0c8dab32,d:f39206b4083e4cd19b36063ecc619265-->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20240502</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-20">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20240502.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-02</xbrli:startDate><xbrli:endDate>2024-05-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if39206b4083e4cd19b36063ecc619265_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 2, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20240502_g1.jpg" alt="crdflogo.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-18">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-19">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Results of Operations and Financial Conditions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2024, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.  </span></div><div style="padding-left:72pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.437%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf033124-q12024pr.htm">Press Release of Cardiff Oncology, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf033124-q12024pr.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf033124-q12024pr.htm"> 2, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf033124-q12024pr.htm">4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> May 2, 2024</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>crdf033124-q12024pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7196829bcf6642a29bf8748a476b2526_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:270px"></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:125%">Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev na&#239;ve patients and support ongoing first-line RAS-mutated mCRC lead program -</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib&#8217;s antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvansertib&#8217;s activity in combination treatments -</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Cash and equivalents of $67 million as of March 31, 2024, projected runway into Q3 2025 -</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Company will hold a conference call today at 4&#58;30 p.m. ET&#47;1&#58;30 p.m. PT -</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">SAN DIEGO, May 2, 2024 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">-- Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;During the start of 2024, we presented several important new data sets supporting our first-line RAS-mutated mCRC strategy and the broader opportunity for onvansertib,&#8221; said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. &#8220;The data from the ONSEMBLE trial replicated, in a second independent and randomized dataset, the bev na&#239;ve signal from our earlier Phase 1b&#47;2 KRAS-mutated mCRC trial. And the Phase 1b data published in the peer-reviewed journal Clinical Cancer Research, and the additional data we presented in one of our five posters at AACR, further substantiated our lead program in RAS-mutated mCRC. The additional AACR posters also point toward new indications for onvansertib in RAS wild-type mCRC, small cell lung cancer and ovarian cancer. Looking ahead, we believe that our upcoming data readout from our first-line trial in RAS-mutated mCRC has the potential to serve as a key value inflection point for our company and revolutionize the treatment of RAS-mutated mCRC, an area with no new treatments approved in over two decades.&#8221;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Upcoming expected milestones</font></div><div style="margin-bottom:8pt;padding-left:38.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">The Company has updated its expectation of the timing for an initial readout from the first-line RAS-mutated metastatic colorectal cancer (mCRC) randomized CRDF-004 trial to 2H 2024, based on the enrollment trends observed from active clinical trial sites </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Company highlights for the quarter ended March 31, 2024 and subsequent weeks include&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:12.53pt">Presented updated data at AACR Annual Meeting 2024 that supports ongoing first-line RAS-mutated mCRC clinical study.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">In a poster titled &#8220;A Phase 1b&#47;2 Clinical Study of Onvansertib in Combination with FOLFIRI&#47;Bev Revealed a New Role of PLK1 in regulating the Hypoxia Pathway in KRAS-mutated mCRC,&#8221; updated clinical and preclinical data further supported the ongoing CRDF-004 Phase 2 trial of onvansertib + chemo&#47;bev for the first-line treatment of RAS-mutated mCRC patients, who by definition are bev na&#239;ve.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">In vitro, onvansertib inhibited activation of the hypoxia pathway through the regulation of transcription factor HIF1&#945; and its downstream targets.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Bev na&#239;ve patients treated with onvansertib + FOLFIRI&#47;bev demonstrated a significantly greater overall response rate &#91;odds ratio&#61;13.64, p&#60;0.001&#93; and longer PFS &#91;hazard ratio&#61;0.21, p&#61;0.003&#93; compared to bev exposed patients. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:12.53pt">Announced first patient dosed for lead program in randomized first-line Phase 2 trial, CRDF-004, for patients with RAS-mutated mCRC.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">The trial, whose clinical execution is being conducted by our partner, Pfizer Ignite, is designed to confirm the dose of onvansertib for a subsequent registrational trial, and generate safety and efficacy data for onvansertib when added to standard of care (SoC) vs. SoC alone. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">Interim topline results from CRDF-004 are expected in 2H 2024. Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:12.53pt">Provided a clinical update on Phase 2 randomized second-line ONSEMBLE trial in mCRC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">New clinical data from second-line randomized ONSEMBLE trial, that closed for enrollment in 2023, provide further evidence of onvansertib&#8217;s role in improving the efficacy of SoC (FOLFIRI+bev) therapy in bev na&#239;ve patients. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">In the trial (n &#61; 21), patients who were bev na&#239;ve and who received onvansertib in combination with SoC demonstrated an objective response rate (ORR) of 50% (2 of 4). No clinical responses were observed in bev na&#239;ve patients who received SoC alone (n &#61; 3), or patients who were previously exposed to bev (n &#61; 14). </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">The ONSEMBLE data serves as a second independent, randomized, prospective data set providing evidence of the strong efficacy signal in bev na&#239;ve patients. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:12.53pt">Announced the publication of data from Phase 1b study in second line KRAS-mutated mCRC in the peer-reviewed journal </font><font style="color:#467886;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">Clinical Cancer Research</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">Findings from the Phase 1b portion of company's Phase 1b&#47;2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with SoC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">These peer-reviewed published data are part of the Phase 1b&#47;2 data announced in August 2023 and informed the shift to investigation in first-line RAS-mutated mCRC (CRDF-004).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:12.53pt">Presented three posters at AACR Annual Meeting 2024 in therapeutic areas outside of RAS-mutated mCRC</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">In a poster titled &#8220;The PLK1 Inhibitor Onvansertib is Active as Monotherapy and in Combination with Cetuximab in RAS Wild-type mCRC Patient-derived Xenografts,&#8221; single agent onvansertib successfully induced tumor stasis or regression in 70% (14&#47;20) of the RAS wild-type mCRC patient-derived xenograft (PDX) models tested which included both models sensitive to cetuximab (5&#47;7, 71%) and resistant to cetuximab (9&#47;13, 69%). Additionally, onvansertib in combination with cetuximab induced tumor stasis or regression in 90% (18&#47;20) of the models tested. The antitumor activity of the combination was superior compared to monotherapy with either agent in both cetuximab sensitive and resistant models.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">In a poster titled &#8220;The PLK1 Inhibitor, Onvansertib, Synergizes with Paclitaxel in Small Cell Lung Cancer (SCLC),&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">onvansertib in combination with paclitaxel was well-tolerated and demonstrated superior efficacy over monotherapies in cisplatin sensitive and resistant SCLC PDX models. These preclinical findings in SCLC and previous data generated in breast cancer suggest that onvansertib in combination with paclitaxel has the potential to become a highly promising combination strategy across multiple cancer indications.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.25pt">In a poster titled &#8220;In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum-resistant ovarian carcinoma patient-derived xenograft models,&#8221; onvansertib was synergistic in vitro in both combinations in an ovarian cancer cell line. Both combinations demonstrated antitumor activity in vivo in platinum-resistant ovarian cancer PDX models and was well tolerated. These data support the potential of onvansertib to improve SoC treatments for platinum-resistant ovarian cancer patients.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">First Quarter 2024 Financial Results</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Liquidity, cash burn, and cash runway</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">As of March 31, 2024, Cardiff Oncology had approximately $67.2 million in cash, cash equivalents, and short-term investments.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Net cash used in operating activities for the first quarter of 2024 was approximately $7.7 million, a decrease of approximately $1.0 million from $8.7 million for the same period in 2023.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into Q3 of 2025.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Operating results</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Total operating expenses were approximately $11.1 million for the three months ended March 31, 2024, a decrease of $1.0 million from $12.1 million for the same period in 2023. The decrease in operating expenses was primarily due to a reduction in chemistry, manufacturing and controls costs compared to the prior period.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Conference Call and Webcast</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cardiff Oncology will host a corresponding conference call and live webcast at 4&#58;30 p.m. ET&#47;1&#58;30 p.m. PT on May 2, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the &#34;Investors&#34; section of the company's website at </font><font style="color:#467886;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. A webcast replay will be available in the investor relations section on the company's website following the completion of the call.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cardiff Oncology, Inc.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit </font><font style="color:#467886;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Forward-Looking Statements</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate&#59; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed&#59; our need for additional financing&#59; risks related to business interruptions, including the outbreak of an epidemic or pandemic such as the COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cardiff Oncology Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">James Levine</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">858-952-7670<br></font><font style="color:#467886;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">jlevine&#64;cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kiki Patel, PharmD </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilmartin Group</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">332-895-3225<br></font><font style="color:#467886;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Kiki&#64;gilmartinir.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Grace Spencer</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Taft Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">609-583-1151</font></div><div><font style="color:#467886;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">grace&#64;taftcommunications.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:8pt;padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7196829bcf6642a29bf8748a476b2526_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands, except for per share amounts)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:71.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,008&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,138&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,135&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,933)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,052)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,011)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,223)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,229)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,678&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i7196829bcf6642a29bf8748a476b2526_7"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Balance Sheets</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,529&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,168&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,990&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,412&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,038&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,637&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,191&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,966&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,956&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,843&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,440&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,144&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,894&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,038&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,637&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i7196829bcf6642a29bf8748a476b2526_10"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Cash Flows</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,011)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,223)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of discounts on short-term investments, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,740)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,659)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases, maturities and sales of short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,329&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,997)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,330)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,658&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crdf-20240502.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7576a009-f97d-4232-a9b6-7afd7f5ded2e,g:b49e9c80-d4d3-4f5c-b13c-b31d0c8dab32-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20240502" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20240502">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20240502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20240502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>crdf-20240502_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7576a009-f97d-4232-a9b6-7afd7f5ded2e,g:b49e9c80-d4d3-4f5c-b13c-b31d0c8dab32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_49f68517-dbe8-473b-924a-12be102e8059_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ac07922c-7387-4424-9d24-0cd3bf48c901_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f62ed8fa-ae87-49fc-9c0a-7589c1b5d06c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_43aba0cb-afd4-4f84-bdce-6ebdbce34bfc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f6297d6f-21b4-4f2e-9889-ad4b4cd427c1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e3420022-6def-4e7a-8efb-ee22dfbeef06_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1579eca5-2513-4a81-9136-813f0a427dca_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_28b23661-d6cc-4c4b-bdfe-00e11be2a8d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f58749e9-2a7c-4e83-b993-719913e78ac4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8e24a1f4-86f2-4390-9010-8ed4462a9220_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_71a3e8c8-539a-45c1-a047-72713d90d1d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_9997bb78-24d6-4b13-a188-8e901a19910f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f6531c6c-30fc-4d5c-8e07-a24de0231172_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e065ceeb-e280-46a7-a4b4-68f96130b780_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d2549006-77e6-4a3d-a76e-314b5fcb056e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_83252d67-151c-4bd2-ae19-6d0f430d4a40_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8914cff1-b2de-4e2c-a3bc-1031e3dde612_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6cbbc1f3-13be-442d-a9c1-1e9a9f690e94_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f8496255-8f66-4b52-9a84-3efbaa3518a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b0dd37d8-0ef7-4137-9052-e77e81768120_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_671bb2e3-1c32-4b38-b39e-004dfa306db9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>crdf-20240502_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7576a009-f97d-4232-a9b6-7afd7f5ded2e,g:b49e9c80-d4d3-4f5c-b13c-b31d0c8dab32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20240502.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f6e756cf-7cf8-46b1-9dd7-b5af11778c02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_DocumentType_f6e756cf-7cf8-46b1-9dd7-b5af11778c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3f500a2d-b14a-44f1-bde1-5ba25b964df9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_DocumentPeriodEndDate_3f500a2d-b14a-44f1-bde1-5ba25b964df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d226992b-f815-4c21-8aee-83c861474c1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityRegistrantName_d226992b-f815-4c21-8aee-83c861474c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b393052f-8838-4a96-bbc4-3e19afd75bce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityFileNumber_b393052f-8838-4a96-bbc4-3e19afd75bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4d7f3088-8d42-4edc-8845-67664450af4e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityTaxIdentificationNumber_4d7f3088-8d42-4edc-8845-67664450af4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_52f1b0f1-51ab-43c9-a1b7-60d7444a0d7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityAddressAddressLine1_52f1b0f1-51ab-43c9-a1b7-60d7444a0d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_33bb9c44-bb87-4ec8-af48-18b871e36a90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityAddressStateOrProvince_33bb9c44-bb87-4ec8-af48-18b871e36a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ca162f0d-4c50-402a-a1af-b82e8854468a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityAddressPostalZipCode_ca162f0d-4c50-402a-a1af-b82e8854468a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_61283c60-fb91-4d6e-ae77-46e54cd9494e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityAddressCityOrTown_61283c60-fb91-4d6e-ae77-46e54cd9494e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4e53e695-7df3-479b-92bf-07c0bd57123d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_CityAreaCode_4e53e695-7df3-479b-92bf-07c0bd57123d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9d9ef6df-de7f-46d7-917e-b7b79e3e930d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_LocalPhoneNumber_9d9ef6df-de7f-46d7-917e-b7b79e3e930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1d1b2837-7de0-434e-82a2-a7cbcc73f148" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_Security12bTitle_1d1b2837-7de0-434e-82a2-a7cbcc73f148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_434d0c05-08bc-4d10-b90c-e9756d9f7612" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_TradingSymbol_434d0c05-08bc-4d10-b90c-e9756d9f7612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4f35316f-5faf-4e64-ad30-85370d0c7f23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_WrittenCommunications_4f35316f-5faf-4e64-ad30-85370d0c7f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_420059ab-1ed3-4406-aaff-59cc1eeaa0f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_SolicitingMaterial_420059ab-1ed3-4406-aaff-59cc1eeaa0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_3c124054-7a3f-4111-9e1e-322444a1097c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_PreCommencementTenderOffer_3c124054-7a3f-4111-9e1e-322444a1097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_49e48752-1946-455f-87f6-81677ac8debf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_49e48752-1946-455f-87f6-81677ac8debf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2b7cc782-770e-4753-adc1-2c68bf25213d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityEmergingGrowthCompany_2b7cc782-770e-4753-adc1-2c68bf25213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ff88df7f-bbf5-4b04-b62a-50e3e98bab8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ff88df7f-bbf5-4b04-b62a-50e3e98bab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ec09e10c-0b9c-4cd4-b507-567113474ae3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_EntityCentralIndexKey_ec09e10c-0b9c-4cd4-b507-567113474ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_34d46082-a4d1-4c25-9cac-b6cc0a8bb6de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6b37cf-caa7-4c29-83cd-60c196e4b318" xlink:to="loc_dei_AmendmentFlag_34d46082-a4d1-4c25-9cac-b6cc0a8bb6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crdf-20240502_g1.jpg
<TEXT>
begin 644 crdf-20240502_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
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M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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5 7)+M=N/[L%'     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139939045419232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5&_&'O7>+SS)U=JZ"_YDE/.56 C[>SXWT/-KE5AF0A52*V)$,O:F]/J&]5Q
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M@/N)AFW4ON-.@_5A?O(O4$L#!!0    ( $&!HEB?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( $&!HE@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 08&B6'813(#N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 08&B6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !!@:)8.];><QH$  #8#P  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 08&B6)^@&_"Q @  X@P   T              ( !70P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !!@:)8EXJ[',     3 @  "P
M@ $Y#P  7W)E;',O+G)E;'-02P$"% ,4    " !!@:)8JL0B%C,!   B @
M#P              @ $B$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M08&B6"0>FZ*M    ^ $  !H              ( !@A$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 08&B6&60>9(9 0  SP,  !,
M             ( !9Q(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  L1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20240502.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="crdf-20240502.htm">crdf-20240502.htm</File>
    <File>crdf-20240502.xsd</File>
    <File>crdf-20240502_lab.xml</File>
    <File>crdf-20240502_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20240502_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crdf-20240502.htm": {
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20240502",
   "dts": {
    "inline": {
     "local": [
      "crdf-20240502.htm"
     ]
    },
    "schema": {
     "local": [
      "crdf-20240502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20240502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20240502_pre.xml"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 22,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 21
   },
   "report": {
    "R1": {
     "role": "http://www.cardiffoncology.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crdf-20240502.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crdf-20240502.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-24-020010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-020010-xbrl.zip
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MH0&FM:RL(QN(^6NS !:F$N%YP7$02WQB 122PPW-L#1S8I)%\)OVQ$03:VH
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M;M=#U_=C8PFHM?C8.)_\15GU9VBK_P=02P,$%     @ 08&B6,6FV"MP @
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M8]?#5F-Q7V3[YT="#(:]NN>#/U!+ P04    " !!@:)8I]:K[P,*  "L"@
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M'G"K%;)6F^!H&VFCHZ@B-[)7L"]X0YMM$\15"!+61*W!UG;_S'X!'[63+M:
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M8 #$'.X>N*#9418J4-">X3V)\"1"Y#?2C?$B($9Z<&H5(>H6G1?8L057 *3
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MYT'%BB++OD;3DM:=,098QBJ&KP,0/4&, 1%NZ$H<!0T4WJK!860%R7BR)+F
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M57(Q(G74XN>N ';!@O@8GZIMPPG;[K] _L#QX-0TZO7M8XY[Q^E3,,N^!'S
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M@$FG7FWWZKL_$\2L@K;;RP$F>UKL9J>M//0 DUZQSN_X-@HX9Q_ANE'(WH(
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MN:_^'U!+ 0(4 Q0    ( $&!HE@^L3KUK X  )5Y   1              "
M 0    !C<F1F+3(P,C0P-3 R+FAT;5!+ 0(4 Q0    ( $&!HEC%IM@K< (
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M,#(T,#4P,E]P<F4N>&UL4$L! A0#%     @ 08&B6*009_LE(@  GY,! !<
M             ( !/2P  &-R9&8P,S,Q,C0M<3$R,#(T<'(N:'1M4$L%!@
0   &  8 BP$  )=.      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>crdf-20240502_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20240502.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2024-05-02</startDate>
            <endDate>2024-05-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-20">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications contextRef="c-1" id="f-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
